Table 5.
Results overview filling the randomised controlled trial gaps with subgroup analyses by biosimilar product in all the indicated pathologies
| Rheumatoid arthritis | Ankylosing spondylitis | Psoriatic arthritis | Crohn’s disease | Ulcerative colitis | Psoriasis | Hidradenitis suppurativa | Uveitis | |
| Infliximab | ||||||||
| CT-P13 | Yoo and colleagues37 | Park and colleagues38 | Ye and colleagues39 | |||||
| SB2 | Choe and colleagues40 | |||||||
| ALL | ||||||||
| Etanercept | ||||||||
| GP2015 | Matucci-Cerinic and colleagues41 | Griffiths and colleagues42 | ||||||
| SB4 | Emery and colleagues43 | |||||||
| ALL | ||||||||
| Adalimumab | ||||||||
| ABP501 | Cohen and colleagues44 | Papp and colleagues45 | ||||||
| FKB327 | Genovese and colleagues46 | |||||||
| SB5 | Weinblatt and colleagues47 | |||||||
| MSB11022 | Edwards and colleagues48 | Hercogova and colleagues49 | ||||||
| GP2017 | Wiland and colleagues50 | Blauvelt and colleagues51 | ||||||
| ALL | ||||||||
Grey box: no persistence difference. Blue box: statistically higher persistence with biosimilar. Brown box: not enough patients to conclude. Blank box: not indicated. Randomised controlled trials are shown, with the authors and reference number of the study in the respective box.